Alnylam Pharmaceuticals | ALNY - Trade Debtors



Alnylam Pharmaceuticals reported $567.11M in Trade Debtors for its fiscal quarter ending in June of 2025.


Trade Debtors Change Date
Acadia Pharmaceuticals USD 119.69M 5.97M Jun/2025
Agios Pharmaceuticals USD 4.99M 1.64M Jun/2025
Alnylam Pharmaceuticals USD 567.11M 149.08M Jun/2025
Amgen USD 8.7B 569M Jun/2025
Arrowhead Research USD 9.7M 7.33M Jun/2025
BioMarin Pharmaceutical USD 855.85M 116.68M Jun/2025
Incyte USD 842.89M 19.76M Jun/2025
Ionis Pharmaceuticals USD 52.58M 12.87M Jun/2025
Moderna USD 457M 151M Jun/2025
Neurocrine Biosciences USD 595.7M 79.7M Jun/2025
Novartis USD 9.18B 1.62B Jun/2025
PTC Therapeutics USD 196.13M 14.36M Jun/2025
Regeneron Pharmaceuticals USD 5.61B 49M Jun/2025
Sanofi 8.21B 2.42B Jun/2025
Sarepta Therapeutics USD 609.6M 114.93M Jun/2025
Takeda JPY 679.53B 45.72B Jun/2025
Tectonic Therapeutic USD 0 270K Dec/2023
Ultragenyx Pharmaceutical USD 124.46M 25.62M Jun/2025
Vertex Pharmaceuticals USD 1.89B 88.4M Jun/2025
Xencor USD 47.55M 9.77M Jun/2025